Monday, 26 January 2009

Lidex-E


See also: Generic Lidex


Lidex-E is a brand name of fluocinonide topical, approved by the FDA in the following formulation(s):


LIDEX-E (fluocinonide - cream; topical)



  • Manufacturer: MEDICIS

    Approved Prior to Jan 1, 1982

    Strength(s): 0.05% [RLD][AB2]

Has a generic version of Lidex-E been approved?


Yes. The following products are equivalent to Lidex-E:


FLUOCINONIDE EMULSIFIED BASE (fluocinonide cream; topical)



  • Manufacturer: FOUGERA PHARMS

    Approval date: June 23, 2004

    Strength(s): 0.05% [AB2]


  • Manufacturer: TARO

    Approval date: January 19, 1989

    Strength(s): 0.05% [AB2]


  • Manufacturer: TEVA

    Approval date: February 7, 1989

    Strength(s): 0.05% [AB2]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lidex-E. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Lidex-E.

See also...

  • Lidex-E Cream Consumer Information (Wolters Kluwer)
  • Lidex-E Consumer Information (Cerner Multum)
  • Lidex-E Advanced Consumer Information (Micromedex)
  • Fluocinonide Cream Consumer Information (Wolters Kluwer)
  • Fluocinonide Gel Consumer Information (Wolters Kluwer)
  • Fluocinonide Solution Consumer Information (Wolters Kluwer)
  • Fluocinonide topical Consumer Information (Cerner Multum)
  • Lidemol Advanced Consumer Information (Micromedex)
  • Lyderm Advanced Consumer Information (Micromedex)
  • Tcis Advanced Consumer Information (Micromedex)
  • Tiamol Advanced Consumer Information (Micromedex)
  • Topsyn Advanced Consumer Information (Micromedex)
  • Trisyn Advanced Consumer Information (Micromedex)
  • Fluocinonide Topical application Advanced Consumer Information (Micromedex)

No comments:

Post a Comment